These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 9518881)

  • 1. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
    Rigamonti AE; Cavallera G; Bonomo S; Deghenghi R; Locatelli V; Cella SG; Müller EE
    Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE; Bonomo SM; Cella SG; Müller EE
    J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin withdrawal as generator of pulsatile GH release in the dog: a possible tool to evaluate the endogenous GHRH tone?
    Cella SG; Luceri M; Cattaneo L; Torsello A; Müller EE
    Neuroendocrinology; 1996 Jun; 63(6):481-8. PubMed ID: 8793889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
    Arce VM; Cella SG; Locatelli V; Müller EE
    Neuroendocrinology; 1991 May; 53(5):467-72. PubMed ID: 1908062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L; Rolla M; Arvat E; Belliti D; Valetto MR; Ferdeghini M; Ghigo E; Müller EE
    Biol Psychiatry; 1999 Feb; 45(3):334-9. PubMed ID: 10023511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.
    Rigamonti AE; Cella SG; Marazzi N; Müller EE
    Eur J Endocrinol; 1999 Sep; 141(3):313-20. PubMed ID: 10474131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
    Müller EE; Rolla M
    Psychiatry Res; 1996 Apr; 62(1):51-63. PubMed ID: 8739115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galanin abolishes the inhibitory effect of cholinergic blockade on growth hormone-releasing hormone-induced secretion of growth hormone in man.
    Chatterjee VK; Ball JA; Proby C; Burrin JM; Bloom SR
    J Endocrinol; 1988 Feb; 116(2):R1-2. PubMed ID: 2450944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.